Newsletter | 01 July 2004 Access News 10, Focus on AIDS Treatment, July 2004 INTELLECTUAL PROPERTY AND TRADE In this edition of AccessNews, the challenges of AIDS treatment is focused on, as well as the importance of patient activism to expand treatment, MSF AIDS programs FDCs and Africa starting to ACT against malaria. Read, watch, share Filter by - Any -BlogEventsFeature storyInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechStatementTechnical briefVideo Photograph by Jan-Joseph Stok Press release Press release | 26 July 2024 HIV/AIDS Pharmaceutical corporation ViiV must urgently supply HIV drug CAB-LA according to global public health needs 5 min Photo credit: MSF Press release Press release | 23 July 2024 HIV/AIDS Activists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot 3 min Technical brief | 05 June 2024 HIV/AIDS Antiretroviral Prices in 2023 Letter | 22 April 2024 Diagnostics Hepatitis C HIV/AIDS Ghana Ghana: National AIDS Control Programme letter to Danaher to reduce the price of GeneXpert test Photo credit: MSF/Martim Gray Pereira Press release Press release | 06 February 2024 HIV/AIDS Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir 5 min Technical brief | 24 November 2023 HIV/AIDS Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP) Photo credit: Njiiri Karago/MSF Press release Press release | 17 August 2023 HIV/AIDS MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA 4 min Photo credit: Jan-Joseph Stok Letter Letter | 17 August 2023 HIV/AIDS Open letter to ViiV to improve access to HIV prevention drug CAB-LA 1 min Load More
Photograph by Jan-Joseph Stok Press release Press release | 26 July 2024 HIV/AIDS Pharmaceutical corporation ViiV must urgently supply HIV drug CAB-LA according to global public health needs 5 min
Photo credit: MSF Press release Press release | 23 July 2024 HIV/AIDS Activists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot 3 min
Letter | 22 April 2024 Diagnostics Hepatitis C HIV/AIDS Ghana Ghana: National AIDS Control Programme letter to Danaher to reduce the price of GeneXpert test
Photo credit: MSF/Martim Gray Pereira Press release Press release | 06 February 2024 HIV/AIDS Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir 5 min
Technical brief | 24 November 2023 HIV/AIDS Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)
Photo credit: Njiiri Karago/MSF Press release Press release | 17 August 2023 HIV/AIDS MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA 4 min
Photo credit: Jan-Joseph Stok Letter Letter | 17 August 2023 HIV/AIDS Open letter to ViiV to improve access to HIV prevention drug CAB-LA 1 min
